News

Biweekly Cabazitaxel Regimen Reduces Occurrence of Neutropenia Among Older Patients With Metastatic Castration-Resistant Prostate Cancer

11/06/2023

Allison Casey

According to results from a phase 3 clinical trial, biweekly cabazitaxel reduced the rate of neutropenia among older patients with metastatic castration-resistant prostate cancer.

According to results from a...

11/06/2023

Oncology

News

Stereotactic Body Radiation Therapy May Benefit Patients With Oligometastatic Castration-Resistant Prostate Cancer

10/13/2023

Allison Casey

In the phase 2 ARTO trial, targeting oligometastatic sites of disease with SBRT and standard-of-care abiraterone acetate was found to enhance response rates and prolong time to radiographic progression among patients with castration-resistant...

In the phase 2 ARTO trial,...

10/13/2023

Oncology

News

Niraparib Plus Abiraterone Acetate and Prednisone Continues to Benefit Patients with HRR-Altered Metastatic Castration-Resistant Prostate Cancer

09/14/2023

Allison Casey

In the second interim analysis of the phase 3 MAGNITUDE trial, niraparib plus abiraterone acetate and prednisone improved the radiographic progression-free survival of patients with metastatic castration-resistant prostate cancer and HRR...

In the second interim analysis...

09/14/2023

Oncology

News

Niraparib Plus Abiraterone Acetate and Prednisone Continues to Benefit Patients with HRR-Altered Metastatic Castration-Resistant Prostate Cancer

09/14/2023

Allison Casey

In the second interim analysis...

09/14/2023

Oncology

News

FDA Approves Niraparib and Abiraterone Acetate Plus Prednisone for Castration-Resistant Prostate Cancer

08/15/2023

Stephanie Holland

On August 11, 2023, the FDA granted approval to niraparib and abiraterone acetate plus prednisone for BRCA-mutated metastatic castration-resistant prostate cancer, based on results from the MAGNITUDE study.

On August 11, 2023, the FDA...

08/15/2023

Oncology

News

Darolutamide Improved Survival Outcomes for Patients With Castration-Resistant Prostate Cancer and Substantial Comorbidity Burden

08/10/2023

Allison Casey

In the phase 3 ARAMIS trial, patients with castration-resistant prostate cancer and high numbers of comorbidities experienced a similar benefit from darolutamide as those in the general trial population.

In the phase 3 ARAMIS trial,...

08/10/2023

Oncology

News

Pembrolizumab-Olaparib Combination Did Not Improve Survival Outcomes Among Patients With Metastatic Castration-Resistant Prostate Cancer

07/20/2023

Allison Casey

In a phase 3 study, pembrolizumab plus olaparib did not improve the progression-free survival or overall survival of patients with metastatic castration-resistant prostate cancer, when compared with next-generation hormonal agents.

In a phase 3 study,...

07/20/2023

Oncology

News

Talazoparib With Enzalutamide Approved for HRR Gene-Mutated Metastatic Castration-Resistant Prostate Cancer

06/21/2023

On June 20, 2023, the US FDA granted approval to talazoparib plus enzalutamide for the treatment of patients with HRR gene-mutated metastatic castration-resistant prostate cancer.

On June 20, 2023, the US FDA...

06/21/2023

Oncology

News

Olaparib Plus Abiraterone and Prednisone Granted FDA Approval for BRCA-Mutated Prostate Cancer

06/02/2023

Allison Casey

On May 31, 2023, the FDA approved olaparib plus abiraterone and prednisone for patients with metastatic castration-resistant prostate cancer with BRCA mutations.

On May 31, 2023, the FDA...

06/02/2023

Oncology

News

Apalutamide vs Abiraterone for Deep PSA Response Among Patients With Castration-Sensitive Prostate Cancer

05/25/2023

Allison Casey

A retrospective study found that patients with castration-sensitive prostate cancer treated with apalutamide were more likely to experience a deep PSA response than those treated with abiraterone acetate.

A retrospective study found that...

05/25/2023

Oncology

Recent News

News

Osimertinib Lacks Activity in Neoadjuvant Setting for Early-Stage Non-Small Cell Lung Cancer With EGFR Mutation

08/08/2024

Stephanie Holland ;

Results from a phase 2 study demonstrated that neoadjuvant osimertinib did not improve the major pathological response rate among patients with early-stage non-small cell lung cancer harboring an EGFR mutation.

Results from a phase 2 study...

08/08/2024

Oncology

FDA Approval

FDA Approves Denileukin Diftitox for Patients With R/R Cutaneous T-Cell Lymphoma

08/08/2024

Amber Denham ;

The US Food and Drug Administration approved novel immunotherapy denileukin diftitox-cxdl for the treatment of patients with relapsed/refractory cutaneous T-cell lymphoma after at least 1 prior systemic therapy.

The US Food and Drug...

08/08/2024

Oncology

News

Tailored Dose-Dense Chemotherapy Improved Survival Outcomes Among Patients With High-Risk Early Breast Cancer

08/07/2024

Stephanie Holland ;

According to results from the phase 3 PANTHER trial, tailored and dose-dense chemotherapy in the adjuvant setting improved survival outcomes compared to standard chemotherapy among patients with high-risk early breast cancer.

According to results from the...

08/07/2024

Oncology

News

Frontline Treatment Management for Patients With FL Reduces Risk of High-Grade Transformation to DLBCL

08/07/2024

Amber Denham ;

A recent study demonstrated that frontline treatment management reduced the risk of high-grade transformation to diffuse large B-cell lymphoma among patients with follicular lymphoma, but not among patients with marginal zone lymphoma.

A recent study demonstrated that...

08/07/2024

Oncology

News

Optimal Sotorasib Dose for Patients With KRAS G12C-Mutated Advanced Non-Small Cell Lung Cancer

08/07/2024

Stephanie Holland ;

Results from a phase 2 study found that 960 mg of sotorasib is preferable to 240 mg among patients with previously treated KRAS G12C-mutated locally advanced or metastatic non-small cell lung cancer.

Results from a phase 2 study...

08/07/2024

Oncology

FDA Approval

FDA Approves Vorasidenib for Patients With IDH1/IDH2-Mutated Grade 2 Astrocytoma or Oligodendroglioma

08/06/2024

Stephanie Holland ;

Based on results from the INDIGO trial, the FDA has approved vorasidenib for adult and pediatric patients 12 years and older with grade 2 astrocytoma or oligodendroglioma with a susceptible IDH1 or IDH2 mutation following surgery.

Based on results from the INDIGO...

08/06/2024

Oncology

FDA Approval

FDA Approves Afamitresgene Autoleucel for Certain Unresectable or Metastatic Synovial Sarcoma

08/02/2024

Allison Casey ;

On August 2, 2024, the US Food and Drug Administration (FDA) granted accelerated approval to afamitresgene autoleucel for the treatment of adult patients with certain unresectable or metastatic synovial sarcomas who had received prior...

On August 2, 2024, the US Food...

08/02/2024

Oncology

FDA Approval

FDA Approves Dostarlimab Plus Chemotherapy for Patients With Primary Advanced or Recurrent Endometrial Cancer

08/01/2024

Allison Casey ;

The FDA approved dostarlimab plus carboplatin and paclitaxel, followed by single-agent dostarlimab for patients with primary advanced or recurrent endometrial cancer.

The FDA approved dostarlimab...

08/01/2024

Oncology

News

Iadademstat and Azacitidine Combination Therapy Demonstrates Manageable Safety, Promising Efficacy for Patients With Newly Diagnosed AML

08/01/2024

Amber Denham ;

The first-line combination of iadademstat and azacitidine demonstrates a manageable safety profile and promising results among patients with acute myeloid leukemia, according to phase 2 results from the ALICE trial.

The first-line combination of...

08/01/2024

Oncology

News

Effect of Food on Selumetinib Dosing for Adolescent Patients With Neurofibromatosis Type 1 With Plexiform Neurofibromas

08/01/2024

Allison Casey ;

In the phase 1 trial, the addition of a low-fat meal with doses of selumetinib did not significantly impact selumetinib exposure or gastrointestinal toxicities among adolescent patients with neurofibromatosis type 1 with plexiform...

In the phase 1 trial, the...

08/01/2024

Oncology